Table 1Baseline Characteristics of Subjects in the Sub-Analysis
Variable |
Pitavastatin+LSM (n=37) |
Only LSM (n=38) |
P value |
Age, yr |
52.9±8.5 |
52.0±9.1 |
NSa
|
Male sex |
22 (59.5) |
25 (65.8) |
NSb
|
BMI, kg/m2
|
26.8±2.2 |
27.1±3.6 |
NSa
|
WC, cm |
91.8±4.4 |
94.3±6.5 |
NSa
|
SBP, mm Hg |
129.6±10.1 |
126.3±11.1 |
NSa
|
DBP, mm Hg |
80.7±6.6 |
80.8±7.3 |
NSa
|
Exercise, time/wk |
|
|
NSb
|
>3 |
15 (40.5) |
18 (47.4) |
1–3 |
10 (27.0) |
6 (15.8) |
Never |
12 (32.4) |
14 (36.8) |
Current smoker |
10 (27.0) |
12 (31.6) |
NSb
|
Alcohol habits, time/wk |
|
|
NSb
|
≥3 |
14 (37.8) |
17 (44.7) |
<3 |
14 (37.8) |
11 (28.9) |
Never |
9 (24.3) |
10 (26.3) |
CHD family history |
9 (24.3) |
9 (23.7) |
NSb
|
FPG, mg/dL |
114.1±11.1 |
116.5±14.9 |
NSa
|
Total cholesterol, mg/dL |
223.6±28.7 |
215.5±26.5 |
NSa
|
HDL-C, mg/dL |
49.2±9.6 |
46.9±10.0 |
NSa
|
LDL-C, mg/dL |
144.7±19.8 |
136.1±24.0 |
NSa
|
Non-HDL-C, mg/dL |
174.4±28.8 |
168.6±24.4 |
NSa
|
TG, mg/dL |
162.4±50.6 |
175.8±72.9 |
NSa
|
hs-CRP, mg/dL |
0.15±0.16 |
0.19±0.32 |
NSa
|
HOMA-IR |
2.9±1.2 |
3.5±1.7 |
NSa
|
Table 2Changes of Metabolic Parameters after 12 Months Intervention in Both Groups
Variable |
Pitavastatin+LSM (n=37) |
LSM only (n=38) |
P valuea
|
Baseline |
12 months |
Change |
Baseline |
12 months |
Change |
TC, mg/dL |
223.6±28.7 |
178.2±25.9 |
–45.4±34.7b
|
215.7±26.8 |
215.7±22.7 |
0±22.5 |
<0.001 |
TG, mg/dL |
162.4±50.6 |
137.7±54.2 |
–24.7±54.1b
|
175.8±72.9 |
179.6±106.6 |
2.7±98.1 |
NS |
HDL-C, mg/dL |
49.2±9.6 |
49.9±9.0 |
0.7±6.2 |
47.2±10.0 |
49.2±8.5 |
2.0±7.3 |
NS |
LDL-C, mg/dL |
144.7±19.8 |
103.0±24.5 |
–41.7±29.6b
|
135.8±24.3 |
134.1±22.3 |
–1.7±23.2 |
<0.001 |
Non-HDL-C, mg/dL |
174.4±28.8 |
138.4±28.7 |
–46.0±34.4b
|
168.6±24.4 |
166.5±22.8 |
–2.0±21.2 |
<0.001 |
ApoB-100/A1 ratio |
0.75±0.17 |
0.55±0.18 |
–0.21±0.16b
|
0.71±0.18 |
0.66±0.13 |
–0.05±0.12b
|
<0.001 |
Adiponectin, µg/mL |
2.40±0.997 |
3.37±1.47 |
0.965±1.38b
|
3.15±1.87 |
3.67±1.76 |
0.519±1.14b
|
NS |
HMW-adiponectin, µg/mL |
2.20±1.30 |
2.61±1.70 |
0.404±1.01b
|
2.20±1.30 |
3.06±2.77 |
0.775±1.07b
|
NS |
ApoB-48, µg/mL |
5.64±1.55 |
5.36±1.75 |
–0.272±2.17 |
5.98±3.20 |
6.36±2.62 |
0.382±4.05 |
NS |
Lp-PLA2, µg/mL |
1.20±0.262 |
1.25±0.251 |
0.048±0.225 |
1.21±0.241 |
1.33±0.316 |
0.116±0.288b
|
NS |
Table 3Changes from Baseline in the Levels of ApoB-48 and Lp-PLA2 according to Their Baseline Values (i.e., Below and Above Median Values)
Variable |
Pitavastatin+LSM (n=37) |
LSM only (n=38) |
P valuea
|
Baseline |
12 months |
Change |
Baseline |
12 months |
Change |
Below median, µg/mL |
|
|
|
|
|
|
|
ApoB-48 |
4.54 (4.02–4.89) |
4.64 (3.83–6.35) |
0.15 (–0.65 to 2.09) |
4.57 (4.11–4.94) |
5.46 (4.70–6.11) |
0.68 (0.21–1.70) |
0.234 |
Lp-PLA2
|
1.02 (0.86–1.17) |
1.12 (0.94–1.38) |
0.16 (0.00–0.30) |
1.02 (0.91–1.11) |
1.22 (1.14–1.30) |
0.19 (0.10–0.33) |
0.331 |
Above median, µg/mL |
|
|
|
|
|
|
|
ApoB-48 |
6.09 (5.62–7.30) |
5.07 (4.67–5.75) |
–0.88 (–2.51 to –0.65)b
|
6.41 (5.64–7.70) |
5.99 (5.11–6.63) |
0.14 (–1.69 to 0.67) |
0.045b
|
Lp-PLA2
|
1.44 (1.27–1.48) |
1.40 (1.27–1.56) |
–0.03 (–0.15 to 0.11) |
1.34 (1.29–1.44) |
1.44 (1.15–1.54) |
0.06 (–0.18 to 0.15) |
0.598 |